Anargyros Xenocostas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anargyros Xenocostas has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Angelina Yee
Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada
1 shared publicationCindy J. Wong
Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada
1 shared publication- Claudio M. Martin
Medicine, Western University, London, Canada
1 shared publication David M.C. Sutton
Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada
1 shared publicationHans A. Messner
Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada
1 shared publication- James Rose
London Health Sciences Center, Divisions of Critical Care & Hematology; Center for Critical Illness Research; Lawson Health Research Institute; University of Western Ontario, 800 Commissioner's Rd. E., London, Ontario, N6A 5W9, Canada
1 shared publication
Latest Publications
- Open Access
- 18 May 2007
- Published by Springer Nature in Critical Care
- Vol. 11 (3) , R58
Erythropoietin improves skeletal muscle microcirculation and tissue bioenergetics in a mouse sepsis model
Introduction: The relationship between oxygen delivery and consumption in sepsis is impaired, suggesting a microcirculatory perfusion defect. Recombinant human erythropoietin (rHuEPO) regulates erythropoiesis and also exerts complex actions promoting the maintenance of homeostasis of the organism under stress. The objective of this study was to test the hypothesis that rHuEPO could improve skeletal muscle capillary perfusion and tissue oxygenation in sepsis. Methods: Septic mice in three experiments received rHu-EPO 400 U/kg subcutaneously 18 hours after cecal ligation and perforation (CLP). The first experiment measured the acute effects of rHuEPO on hemodynamics, blood counts, and arterial lactate level. The next two sets of experiments used intravital microscopy to observe capillary perfusion and nicotinamide adenine dinucleotide (NADH) fluorescence post-CLP after treatment with rHuEPO every 10 minutes for 40 minutes and at 6 hours. Perfused capillary density during a three-minute observation period and NADH fluorescence were measured. Results: rHuEPO did not have any effects on blood pressure, lactate level, or blood cell numbers. CLP mice demonstrated a 22% decrease in perfused capillary density compared to the sham group (28.5 versus 36.6 capillaries per millimeter; p < 0.001). Treatment of CLP mice with rHuEPO resulted in an immediate and significant increase in perfused capillaries in the CLP group at all time points compared to baseline from 28.5 to 33.6 capillaries per millimeter at 40 minutes; p < 0.001. A significant increase in baseline NADH, suggesting tissue hypoxia, was noted in the CLP mice compared to the sham group (48.3 versus 43.9 fluorescence units [FU]; p = 0.03) and improved with rHuEPO from 48.3 to 44.4 FU at 40 minutes (p = 0.02). Six hours after treatment with rHuEPO, CLP mice demonstrated a higher mean perfused capillary density (39.4 versus 31.7 capillaries per millimeter; p < 0.001) and a lower mean NADH fluorescence as compared to CLP+normal saline mice (49.4 versus 52.7 FU; p = 0.03). Conclusion: rHuEPO produced an immediate increase in capillary perfusion and decrease in NADH fluorescence in skeletal muscle. Thus, it appears that rHuEPO improves tissue bioenergetics, which is sustained for at least six hours in this murine sepsis model.
- 18 May 2007
- Published by Springer Nature in Critical Care
- Vol. 11 (3) , R58
Open AccessErythropoietin improves skeletal muscle microcirculation and tissue bioenergetics in a mouse sepsis model
Introduction: The relationship between oxygen delivery and consumption in sepsis is impaired, suggesting a microcirculatory perfusion defect. Recombinant human erythropoietin (rHuEPO) regulates erythropoiesis and also exerts complex actions promoting the maintenance of homeostasis of the organism under stress. The objective of this study was to test the hypothesis that rHuEPO could improve skeletal muscle capillary perfusion and tissue oxygenation in sepsis. Methods: Septic mice in three experiments received rHu-EPO 400 U/kg subcutaneously 18 hours after cecal ligation and perforation (CLP). The first experiment measured the acute effects of rHuEPO on hemodynamics, blood counts, and arterial lactate level. The next two sets of experiments used intravital microscopy to observe capillary perfusion and nicotinamide adenine dinucleotide (NADH) fluorescence post-CLP after treatment with rHuEPO every 10 minutes for 40 minutes and at 6 hours. Perfused capillary density during a three-minute observation period and NADH fluorescence were measured. Results: rHuEPO did not have any effects on blood pressure, lactate level, or blood cell numbers. CLP mice demonstrated a 22% decrease in perfused capillary density compared to the sham group (28.5 versus 36.6 capillaries per millimeter; p < 0.001). Treatment of CLP mice with rHuEPO resulted in an immediate and significant increase in perfused capillaries in the CLP group at all time points compared to baseline from 28.5 to 33.6 capillaries per millimeter at 40 minutes; p < 0.001. A significant increase in baseline NADH, suggesting tissue hypoxia, was noted in the CLP mice compared to the sham group (48.3 versus 43.9 fluorescence units [FU]; p = 0.03) and improved with rHuEPO from 48.3 to 44.4 FU at 40 minutes (p = 0.02). Six hours after treatment with rHuEPO, CLP mice demonstrated a higher mean perfused capillary density (39.4 versus 31.7 capillaries per millimeter; p < 0.001) and a lower mean NADH fluorescence as compared to CLP+normal saline mice (49.4 versus 52.7 FU; p = 0.03). Conclusion: rHuEPO produced an immediate increase in capillary perfusion and decrease in NADH fluorescence in skeletal muscle. Thus, it appears that rHuEPO improves tissue bioenergetics, which is sustained for at least six hours in this murine sepsis model.
- 12 March 2003
- Published by Wiley in Transfusion
- Vol. 43 (3) , 373-382
RBC transfusion requirements after allogeneic marrow transplantation: impact of the before‐transplant Hb level on transfusion and early survival
BACKGROUND: Most patients undergoing allogeneic marrow transplantation (alloBMT) require transfusions of RBCs. A retrospective analysis was performed to evaluate the utilization and risk factors for RBC transfusions including age and sex of recipient, HLA matching between donor and recipient, disease status at time of BMT, the occurrence of GVHD, ABO blood group compatibility, the source of progenitor cells and the Hb level before BMT (PT‐Hb).STUDY DESIGN AND METHODS: Data from 519 consecutive patients receiving transplants between January 1995 and March 2000 were reviewed. The number of RBC transfusions was determined for the following periods: 0 to 60, 61 to 120, and 121 to 180 days after BMT.RESULTS: The transfusion requirements were greatest during the first 60 days after BMT and decreased with time. The total number of units transfused to this cohort of patients was 5398, of which 3505 units were utilized within the first 2 months. The mean number ± SD of units transfused per patient from 0 to 60 days was 6.8 ± 6.4; 61 to 120 days, 3.2 ± 5.5; and 121 to 180 days, 2.0 ± 4.6. An increased transfusion requirement was associated with lower PT‐Hb, major ABO mismatch between donor and recipient, BMT in patients with more advanced disease, use of unrelated donors, older age, and female sex by Spearman's correlation analysis. The source of progenitor cells and the development of GVHD did not influence transfusion requirements. Increased mortality during the 6‐month period after transplant was associated with lower PT‐Hb, use of unrelated donors, advanced disease status at BMT, and sex by Cox regression analysis. In a multivariate model, PT‐Hb remained significant when controlling for the other risk factors.CONCLUSION: The PT‐Hb was identified as an independent risk factor for RBC transfusions during alloBMT. As well, a lower PT‐Hb was found to be an independent risk factor for increased mortality during the 6‐month study period.
- 12 March 2003
- Published by Wiley in Transfusion
- Vol. 43 (3) , 373-382
RBC transfusion requirements after allogeneic marrow transplantation: impact of the before‐transplant Hb level on transfusion and early survival
BACKGROUND: Most patients undergoing allogeneic marrow transplantation (alloBMT) require transfusions of RBCs. A retrospective analysis was performed to evaluate the utilization and risk factors for RBC transfusions including age and sex of recipient, HLA matching between donor and recipient, disease status at time of BMT, the occurrence of GVHD, ABO blood group compatibility, the source of progenitor cells and the Hb level before BMT (PT‐Hb).STUDY DESIGN AND METHODS: Data from 519 consecutive patients receiving transplants between January 1995 and March 2000 were reviewed. The number of RBC transfusions was determined for the following periods: 0 to 60, 61 to 120, and 121 to 180 days after BMT.RESULTS: The transfusion requirements were greatest during the first 60 days after BMT and decreased with time. The total number of units transfused to this cohort of patients was 5398, of which 3505 units were utilized within the first 2 months. The mean number ± SD of units transfused per patient from 0 to 60 days was 6.8 ± 6.4; 61 to 120 days, 3.2 ± 5.5; and 121 to 180 days, 2.0 ± 4.6. An increased transfusion requirement was associated with lower PT‐Hb, major ABO mismatch between donor and recipient, BMT in patients with more advanced disease, use of unrelated donors, older age, and female sex by Spearman's correlation analysis. The source of progenitor cells and the development of GVHD did not influence transfusion requirements. Increased mortality during the 6‐month period after transplant was associated with lower PT‐Hb, use of unrelated donors, advanced disease status at BMT, and sex by Cox regression analysis. In a multivariate model, PT‐Hb remained significant when controlling for the other risk factors.CONCLUSION: The PT‐Hb was identified as an independent risk factor for RBC transfusions during alloBMT. As well, a lower PT‐Hb was found to be an independent risk factor for increased mortality during the 6‐month study period.